Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M

The company is founded and led by MPM Capital partner and cancer researcher Daniel Hicklin, who oversaw the development of Merck’s immuno-oncology drug Keytruda and other cancer products.